Overview

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

Status:
Completed
Trial end date:
2017-02-16
Target enrollment:
Participant gender:
Summary
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.
Phase:
Phase 3
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Co., Ltd.
Treatments:
Lurasidone Hydrochloride